Gary Deng1. 1. Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
Background: High-symptom burdens, including pain, are associated with high-dose chemotherapy. Objective: We conducted a pilot study to evaluate how acupuncture may affect symptom burden and use of pain medication. Design: This is a randomized sham acupuncture (SA) controlled trial. Setting: An academic cancer center. Patients: Patients were with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Intervention: Once daily acupuncture for 5 days after high-dose chemotherapy. Main Outcome Measures: M. D. Anderson Symptom Inventory (MDASI), opioid use. Results: Compared with SA, true acupuncture reduced nausea, poor appetite, and drowsiness, and use of opioids in opioid-naive patients. Randomizations: Yes. Blinding: Investigators and study participants were blinded. Conclusion: Further study of acupuncture in a larger trial is warranted for its effect on reducing opioid use and symptom burdens during high-dose chemotherapy. Registration: NCT01811862. Copyright 2020, Mary Ann Liebert, Inc., publishers.
RCT Entities:
Background: High-symptom burdens, including pain, are associated with high-dose chemotherapy. Objective: We conducted a pilot study to evaluate how acupuncture may affect symptom burden and use of pain medication. Design: This is a randomized sham acupuncture (SA) controlled trial. Setting: An academic cancer center. Patients: Patients were with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Intervention: Once daily acupuncture for 5 days after high-dose chemotherapy. Main Outcome Measures: M. D. Anderson Symptom Inventory (MDASI), opioid use. Results: Compared with SA, true acupuncture reduced nausea, poor appetite, and drowsiness, and use of opioids in opioid-naive patients. Randomizations: Yes. Blinding: Investigators and study participants were blinded. Conclusion: Further study of acupuncture in a larger trial is warranted for its effect on reducing opioid use and symptom burdens during high-dose chemotherapy. Registration: NCT01811862. Copyright 2020, Mary Ann Liebert, Inc., publishers.
Authors: Gary Deng; Sergio Giralt; David J Chung; Heather Landau; Jonathan Siman; Benjamin Search; Marci Coleton; Emily Vertosick; Nathan Shapiro; Christine Chien; Xin S Wang; Barrie Cassileth; Jun J Mao Journal: Support Care Cancer Date: 2017-09-17 Impact factor: 3.603
Authors: Marlene Z Cohen; Cathy L Rozmus; Tito R Mendoza; Nikhil S Padhye; Joyce Neumann; Ibrahima Gning; Ana Aleman; Sergio Giralt; Charles S Cleeland Journal: J Pain Symptom Manage Date: 2012-06-13 Impact factor: 3.612
Authors: Erica Campagnaro; Rima Saliba; Sergio Giralt; Linda Roden; Floralyn Mendoza; Ana Aleman; Charles Cleeland; Donna Weber; Jane Brown; Karen O Anderson Journal: Cancer Date: 2008-04-01 Impact factor: 6.860